Phibro Animal Health Corporation (PAHC) - Stock Analysis

Last updated: Mar 9, 2026

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Phibro Animal Health exhibits strong earnings growth, margin expansion, cash flow strength, and a 42% price surge over the last month, making it a hot short-term idea with a solid fundamental and technical growth profile.

Loading chart data...

Idea window: 9/2/2025 – 9/9/2025Sector: Healthcare

AI Analyst Overview

Last Price
$49.47
Market Cap
$2.01B
1D Return
+0.96%
YTD Return
+32.73%

Loading chart data...

Valuation Metrics

P/E
21.8
P/B
6.0
P/S
1.4
EV/EBITDA
12.1
Div Yield
0.97%

Fundamental Analysis

7.0

Key Financial Insights: • Margin expansion • Strong liquidity • Elevated leverage PAHC shows materially improved profitability and cash generation with strong short-term liquidity, but elevated debt and very large inventories pose solvency and operational risks.

ImprovingMargins
HighLeverage

Price Behavior

6.0

Key Price Behavior Insights: • Below SMA • Support breached • Momentum weakening Support Level: $48.00 Resistance Level: $54–$55 PAHC has rolled into a short-term downtrend over the last month—closing well below its 21-day SMA with RSI ~35, having breached $49–$50 support and leaving ~$48 as the immediate support while $54–$55 sits as nearby resistance.

weakness
watch

Sentiment & News

6.0

Key News Insights: • Investor outreach • Conflicting coverage • Significant insider selling Phibro's recent investor outreach and bullish screens contrast with a “Hold” consensus and notable insider sales following a strong Q2, signaling mixed signals for the stock.

Momentum
InsiderSales
AI

AI Summary

6.0
Neutral

Phibro's MFA-driven acquisition has meaningfully boosted margins and scale but recasts the stock as an acquisition-dependent, execution-sensitive turnaround—monitor quarterly inventory turns and net leverage reduction (not just reported EBITDA) as the single decisive read on whether upside is sustainable or the balance sheet will constrain returns. #M&A​

Leverage
Execution
AI summary updated 5 days ago

Description

Phibro Animal Health Corporation manufactures and sells a range of animal health and mineral nutrition products for livestock, operating through Animal Health, Mineral Nutrition, and Performance Products segments. Its portfolio includes pharmaceutical treatments and vaccines for poultry, swine and cattle, nutritional additives and trace mineral formulations, plus specialty ingredients used in non-food industries. The company distributes products to integrators, feed manufacturers and distributors across North America, Latin America, Europe, the Middle East, Africa and the Asia Pacific from its headquarters in Teaneck, New Jersey.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Sep 2Sep 9PAHCPhibro Animal Health Corporation
Phibro Animal Health exhibits strong earnings growth, margin expansion, cash flow strength, and a 42% price surge over the last month, making it a hot short-term idea with a solid fundamental and technical growth profile.
Closed+12.8%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.